in a typical year in England, there are ~36,000 admissions for bronchiolitis (mainly caused by Respiratory Syncytial Virus, RSV) in infants under the age of 1 thorax.bmj.com/content/75/3/2… 3/n
this was reflected in emergency department attendances for bronchiolitis across Scotland
in contrast to a usual winter peak, there were very few attendances, most likely representing ongoing rhinovirus circulation (@P_H_S_Official data) 5/n
much of the Southern Hemisphere saw a similar pattern
in France, where schools have remained open throughout the winter and into spring, there is an unusual pattern to this year's epidemic, with a delayed start, and it isn't clear yet whether the peak has been reached santepubliquefrance.fr/maladies-et-tr…@SantePubliqueFr 7/n
what will happen in the UK?
very hard to predict & only a prospective study, collecting and releasing data in real time will allow us to see what is happening and act on this information
1. A larger unexposed cohort than usual with less maternal protection through recent RSV exposure, leads to larger peak than usual
2. Ongoing restrictions mean that we see a smaller peak, with rebound peak this autumn/winter when restrictions fully released 9/n
will RSV spread in its usual pattern (seeding through the metropolitan centres of London and Manchester thorax.bmj.com/content/75/3/2…@ThoraxBMJ ) or in a slower wave from France/Belgium northwards? 10/n
will we see an initial peak of rhinovirus bronchiolitis as restrictions are eased, followed by a delayed RSV peak? 11/n
all open questions, and in my opinion much more of a reason to worry about our summer holidays than vaccine passports
we need this information to understand how infants and children will present to EDs, guide decisions on palivizumab, and inform PICU service planning 12/n
we welcome comments on the study pre-protocol medrxiv.org/content/10.110… & participation of your emergency department through the PERUKI network
we thank all the people who have contributed towards the design of this study so far 13/n
and hope that this study, and others like it, will contribute towards the introduction of an effective RSV vaccine path.org/resources/rsv-… END
• • •
Missing some Tweet in this thread? You can try to
force a refresh
firstly: why should we vaccinate?
-to protect children, who can (rarely) develop severe disease, require hospitalisation, and (very rarely) die
-to protect vulnerable individuals who have contact with children
-to achieve herd immunity: 21% of UK population aged under 18 2/n
secondly, what do we need to vaccinate children?
-a vaccine that robustly protects against severe disease AND prevents transmission
-robust safety data, including paediatric-focused studies & post-licensure monitoring for potential rare outcomes like vaccine-associated MIS-C 3/n
to allow sporting events to take place this summer?
Israel Start-Up Nation, a cycling team, already in "close talks with the Israeli Ministry of Health to assess whether, if there are vaccines available after the main programme takes place, the team can be allocated some.” 2/4
and if athletes merit preferential treatment, should other cultural figures (actors, musicians) get preferential treatment too?
I would argue not, but interested to see what @Twitter thinks 3/4
left pie chart shows neutralisation of original D614G variant by convalescent sera: dark blue= high neutralisation titres, and light blue = lower titres 2/5
right pie chart shows neutralisation of 501Y.V2 variant by same convalescent sera samples: red means loss of neutralising activity (red/black in columns below)
this loss is seen in 21/44 (48%) of total patient samples; only 3 samples retain high neutralising activity 3/5